ZA202006963B - A substituted oxopyridine derivative - Google Patents

A substituted oxopyridine derivative

Info

Publication number
ZA202006963B
ZA202006963B ZA2020/06963A ZA202006963A ZA202006963B ZA 202006963 B ZA202006963 B ZA 202006963B ZA 2020/06963 A ZA2020/06963 A ZA 2020/06963A ZA 202006963 A ZA202006963 A ZA 202006963A ZA 202006963 B ZA202006963 B ZA 202006963B
Authority
ZA
South Africa
Prior art keywords
prophylaxis
diseases
amino
disorders
preparation
Prior art date
Application number
ZA2020/06963A
Other languages
English (en)
Inventor
Mario Lobell
Hartmut Schirok
Adrian Tersteegen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of ZA202006963B publication Critical patent/ZA202006963B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ZA2020/06963A 2018-04-10 2020-11-09 A substituted oxopyridine derivative ZA202006963B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18166490 2018-04-10
PCT/EP2019/058398 WO2019197244A1 (en) 2018-04-10 2019-04-03 A substituted oxopyridine derivative

Publications (1)

Publication Number Publication Date
ZA202006963B true ZA202006963B (en) 2025-05-28

Family

ID=61965754

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/06963A ZA202006963B (en) 2018-04-10 2020-11-09 A substituted oxopyridine derivative

Country Status (17)

Country Link
US (1) US11884660B2 (https=)
EP (1) EP3774796B1 (https=)
JP (1) JP7333336B2 (https=)
KR (1) KR102858566B1 (https=)
CN (1) CN111902414B (https=)
AU (1) AU2019251699B2 (https=)
BR (1) BR112020018237A2 (https=)
CA (1) CA3096480A1 (https=)
DK (1) DK3774796T3 (https=)
ES (1) ES2922533T3 (https=)
IL (1) IL277811B2 (https=)
MX (1) MX2020010635A (https=)
PE (1) PE20210165A1 (https=)
SA (1) SA520420308B1 (https=)
SG (1) SG11202008352YA (https=)
WO (1) WO2019197244A1 (https=)
ZA (1) ZA202006963B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途
CN116947818B (zh) * 2023-09-18 2023-12-19 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
CA2918814C (en) 2013-07-23 2021-10-12 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
EP3063150B1 (de) 2013-10-30 2017-11-22 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN105829298B (zh) 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
US10077265B2 (en) 2014-09-24 2018-09-18 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US10414731B2 (en) 2014-09-24 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
EP3197889B1 (de) 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197891B1 (de) 2014-09-24 2018-11-21 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
CN106687458B (zh) 2014-09-24 2020-10-27 拜耳制药股份公司 取代的氧代吡啶衍生物
EP3197872B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen
CA2979937A1 (en) 2015-03-19 2016-09-22 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3344618A1 (de) 2015-09-04 2018-07-11 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
BR112019003557A2 (pt) 2016-08-31 2019-05-21 Jiangsu Hengrui Medicine Co., Ltd. derivados de oxopicolinamida, método de preparação dos mesmos e uso farmacêutico dos mesmos

Also Published As

Publication number Publication date
US20210147414A1 (en) 2021-05-20
AU2019251699A1 (en) 2020-09-24
WO2019197244A1 (en) 2019-10-17
DK3774796T3 (da) 2022-07-18
CA3096480A1 (en) 2019-10-17
IL277811B2 (en) 2023-12-01
CN111902414A (zh) 2020-11-06
IL277811A (en) 2020-11-30
MX2020010635A (es) 2020-10-28
BR112020018237A2 (pt) 2020-12-29
KR102858566B1 (ko) 2025-09-12
EP3774796B1 (en) 2022-04-27
ES2922533T3 (es) 2022-09-16
AU2019251699B2 (en) 2024-02-29
JP2021521132A (ja) 2021-08-26
IL277811B1 (en) 2023-08-01
SA520420308B1 (ar) 2022-09-29
JP7333336B2 (ja) 2023-08-24
SG11202008352YA (en) 2020-09-29
PE20210165A1 (es) 2021-01-26
US11884660B2 (en) 2024-01-30
CN111902414B (zh) 2023-08-04
EP3774796A1 (en) 2021-02-17
KR20200141445A (ko) 2020-12-18

Similar Documents

Publication Publication Date Title
PH12018500057A1 (en) Substituted oxopyridine derivatives
PH12020551973A1 (en) Substituted dihydropyrazolo pyrazine carboxamide derivatives
WO2019028306A3 (en) COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
WO2018042438A3 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
NO20082044L (no) Kombinasjonsterapi innbefattende substituerte oksazolidinoner for prevensjon og behandling av cerebrale kretslopssykdommer
JOP20210161A1 (ar) مشتقات أكسوبيريدين تحمل بدائل
BR112015024414A2 (pt) derivados de oxopiridina substituída e uso desses no tratamento de distúrbios cardiovasculares
MX2021007069A (es) 3,3-difluoroalilaminas o sales de las mismas y composiciones farmaceuticas que comprenden las mismas.
HK1250752A1 (zh) 治疗骨髓增生性障碍的方法
EA033284B1 (ru) ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
HK1249736A1 (zh) 布鲁顿氏酪氨酸激酶抑制剂的共结晶体
HK1249737A1 (zh) 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式
ZA202006963B (en) A substituted oxopyridine derivative
TN2009000503A1 (en) Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation
CR20240114A (es) Derivados de s–alaninato sustituidos
MA38925A1 (fr) Dérivés de phénylalanine substitués
BR112022003686A2 (pt) Tratamento de sintomas induzidos pelo ciclo menstrual
ZA200908583B (en) Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation
ATE380188T1 (de) Substituierte chinolone
MX383514B (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]piridazin-4-onas como inhibidores de la proteína quinasa.
TW200635920A (en) Pyrazinedicarboxamides and their use
BR112022006501A2 (pt) Composto que tem atividade inibitória de brd4, método de preparação do mesmo e uso do mesmo
BR112018073061A2 (pt) 5,6,7,8-tetra-hidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas e 2,5,6,7-tetra-hidro-3h-pirrolo[2,1-c][1,2,4]triazol-3-onas e seu uso